Urs Hagemann

Urs Hagemann

Company: Bayer

Job title: Laboratory Head


  • Ained biologist (University of Freiburg, Germany) with PhD rer. nat. in protein engineering
  • Ten years of experience in the pharmaceutical industry from early drug discovery to clinical development in oncology
  • Since 2012, focusing on the development of targeted alpha emitting radiopharmaceuticals
  • Proven track record in antibody-based therapeutics including radiopharmaceuticials


Panel Discussion: Are Targeted Alpha Emitting Therapies the Endgame of Radiopharmaceutical Progress? 3:00 pm

Join a panel of experts to discuss: What could improve Alpha emitting isotopes further? What new oncological and non-oncological diseases can we target next? Have Beta-emitting therapies have reached their maximum potential?Read more

day: Day One

Targeted Thorium-227 Conjugates – Exploring the potential of Bayer’s’ novel targeted alpha therapy platform in solid tumors 2:00 pm

Learn Targeted thorium-227 conjugates (TTCs) represent a new class of molecules for targeted alpha therapy (TAT) The covalent attachment of a 3,2-HOPO chelator to targeting moieties ( e.g. tumor antigen targeting antibodies) enables specific complexation and delivery of the alpha particle emitter thorium-227 to tumor cells Due to the high linear energy transfer and short…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.